24.16

1.64% 0.39

Pre-market: 24.10 -0.06 -0.25%

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $24.16, with a volume of 1.20M. It is up +1.64% in the last 24 hours and up +15.10% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$23.77

Open:

$23.65

24h Volume:

1.20M

Relative Volume:

0.64

Market Cap:

$2.64B

Revenue:

Net Income/Loss:

$-237.54M

P/E Ratio:

-9.6513

EPS:

-2.5033

Net Cash Flow:

$-145.05M

1W Performance:

+5.27%

1M Performance:

+15.10%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$23.47

$24.28

1-Week Range:

$22.73

$25.23

52-Week Range:

$14.62

$26.25

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	24.16	2.59B	0	-237.54M	-145.05M	-2.5033
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Stifel	Buy
Apr-10-26	Initiated	Piper Sandler	Overweight
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

Jun 16, 2026

Definium Therapeutics Announces New Employee Inducement GrantsJune 15, 2026 - BioSpace

Jun 16, 2026

Jun 15, 2026

Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan

Jun 15, 2026

Definium Therapeutics (DFTX) director awarded RSUs and stock options in new grant - Stock Titan

Jun 15, 2026

Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs - Stock Titan

Jun 15, 2026

Definium Therapeutics (DFTX) director granted RSUs and stock options in equity award - Stock Titan

Jun 15, 2026

Definium Therapeutics (DFTX) director granted RSUs and 19,188 stock options - Stock Titan

Jun 15, 2026

Six new Definium hires receive options on 155,480 shares - Stock Titan

Jun 15, 2026

Jun 13, 2026

Definium Therapeutics, Inc. Announces 2026 Annual Meeting Results and Key SEC Filings - Minichart

Jun 13, 2026

Jun 12, 2026

Definium Therapeutics (NASDAQ: DFTX) OKs 5M-share equity plan boost - Stock Titan

Jun 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 12, 2026

How Approaching DT120 Phase III Readouts At Definium Therapeutics (DFTX) Have Changed Its Investment Story - Sahm

Jun 12, 2026

Jun 11, 2026

Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 11, 2026

DFTX: Director elections, auditor appointment, and equity plan amendment approved; clinical trial results expected late Q2 - TradingView

Jun 11, 2026

Jun 08, 2026

Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat

Jun 08, 2026

Jun 07, 2026

A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum - Yahoo Finance

Jun 07, 2026

Jun 06, 2026

LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $44 - Moomoo

Jun 06, 2026

Jun 05, 2026

Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com Nigeria

Jun 05, 2026

LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $44 - Moomoo

Jun 05, 2026

Jun 01, 2026

Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN

Jun 01, 2026

May 30, 2026

Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN

May 30, 2026

May 27, 2026